Medtronic stock gets November 24 results date after ablation data
Published on 11/06/2026 at 11:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMedtronic Sets Next Results Milestone
- Medtronic will publish fiscal second-quarter results on November 24, 2026.
- Recent registry findings support the company's cardiac ablation portfolio across atrial and ventricular arrhythmias.
- The ventricular evidence remains an early clinical signal rather than revenue guidance.
Medtronic plc has set November 24, 2026, as the date for its fiscal second-quarter results, giving investors the next scheduled checkpoint for revenue, margins and demand. The company announced the date on November 4 in a Medtronic press release.
The report will cover the fiscal second quarter ended October 30. Medtronic said its financial release will be issued at 5:45 a.m. Central Time, followed by a webcast at 6:30 a.m. Central Time. A replay and transcript are scheduled to become available within 24 hours of the webcast.
Clinical Evidence Shapes Investor Focus
The upcoming report follows recent real-world registry findings for Medtronic's cardiac ablation systems. The evidence covers the Affera Mapping and Ablation System with the Sphere-9 catheter and the PulseSelect pulsed field ablation system in patients with atrial fibrillation and ventricular tachycardia.
The APEX registry included 1,050 atrial fibrillation patients treated with Sphere-9 across 28 sites and reported a 1.1 percent major complication rate. The REAL PULSE registry covered 1,160 atrial fibrillation patients across 38 sites, with 100 percent acute procedural success and a 0.09 percent acute major complication rate.
A separate European analysis of 46 patients with sustained ventricular tachycardia reported 87 percent acute success and estimated six-month freedom from recurrence of 75 percent. The smaller cohort is an early clinical signal, not revenue guidance. Medtronic says Sphere-9 is CE marked for ventricular tachycardia in applicable markets but remains investigational and not approved for that indication in the United States.
Results Will Test Portfolio Execution
The November report will show how the remaining cardiovascular, neuroscience and surgical businesses are progressing after Medtronic completed the separation of MiniMed. Investors are likely to focus on demand, margins and any discussion of commercial adoption for the electrophysiology portfolio.
Medtronic stock traded at 92.67 euros on Lang & Schwarz at 11:42 CET on Friday, November 6, 2026; the real-time quote of Medtronic stock is available for live monitoring.
Medtronic plc at a Glance
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- NYSE ticker: MDT
- Lang & Schwarz quote: 92.67 euros, Friday, November 6, 2026, 11:42 CET
- Business focus: Healthcare technology and cardiac ablation
US equity conditions can be followed through the S&P 500 market environment.
Investors will next focus on the November 24 results and any update on electrophysiology adoption. More news and analyses on Medtronic stock.
